Building on these advances, the ASTRUM-007 trial, initiated in 2019, enrolled Chinese patients with PD-L1 CPS ≥ 1 ESCC, and adopted a more intensive every 2 weeks (Q2W) dosing schedule of serplulimab plus FP chemotherapy (10). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.